Multiple Myeloma: Current Clinical Landscape and Compounding Costs.
Kelsey BeckTyler SandahlSikander AilawadhiNandita KheraChelsee Jo JensenPublished in: Current hematologic malignancy reports (2023)
With the recent passing of the Inflation Reduction Act (IRA), we postulate how costs may be impacted and debate future policy initiatives that may result in sustainability. The IRA will impact drug pricing and likely reduce the costs of some treatments used in MM; there is still a lot of room for policy reform to reduce financial toxicity to patients and prevent depletion of the Medicare trust fund.
Keyphrases
- end stage renal disease
- public health
- healthcare
- multiple myeloma
- ejection fraction
- health insurance
- mental health
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- oxidative stress
- prognostic factors
- current status
- single cell
- quality improvement
- young adults
- social media
- patient reported outcomes
- adverse drug
- life cycle